All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Awards Orphan Drug Designation to Avutometinib Alone or With Defactinib for Recurrent Low-Grade Serous Ovarian Cancer

March 6th 2024

Avutometinib alone or in combination with defactinib has received an orphan drug from the FDA for recurrent low-grade serous ovarian cancer.

EMA Receives Indication Extension Application for D-VRd in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

March 6th 2024

The EMA has received a type II variation application for an indication extension of D-VRd for the treatment newly diagnosed multiple myeloma.

T-DXd Fails to Receive Recommendation From NICE for HER2-Low Breast Cancer Treatment

March 6th 2024

The UK’s NICE has announced that it will not recommend the use of trastuzumab deruxtecan for the treatment of patients with HER2-low breast cancer.

Clinicians Report Unmet Needs Regarding Training Fellows for Community-Based Careers

March 6th 2024

Clinicians say that there are substantial unmet needs in terms of deliberately training hematology/oncology fellows for community-based careers.

Randall Details Inaugural Birmingham Orthopedic Oncology Meeting

March 6th 2024

R. Lor Randall, MD, FACS, discusses the top takeaways from the inaugural 2024 Birmingham Orthopedic Oncology Meeting.

Endoscopy and ctDNA Assays May Help Facilitate, Optimize Nonoperative Management of Select GI Cancers

March 5th 2024

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA assays to guide nonoperative approaches in select gastrointestinal cancers.

Iopofosine Plus EBRT Produces Remissions, Proves Safe in Recurrent/Metastatic Head and Neck Cancer

March 5th 2024

Iopofosine plus EBRT elicited a 64% CR rate and was well tolerated in patients with locoregionally recurrent/metastatic head and neck cancer.

FDA Approves 2 Denosumab Biosimilars for All Reference Medicine Indications

March 5th 2024

The FDA has approved the biosimilars denosumab-bddz (Wyost) and denosumab-bddz (Jubbonti) for use in all indications of the reference medicines denosumab (Xgeva) and denosumab (Prolia).

Frontline Lenvatinib Plus Pembrolizumab Generates Responses But Fails to Produce OS Benefit in HNSCC

March 5th 2024

Adding lenvatinib to pembrolizumab improved ORR and PFS, but not OS, vs placebo for patients with head and neck squamous cell carcinoma.

Kidney Cancer Treatments and Tumor Biology Can Activate Different Immune-Modifying Processes in Patients

March 5th 2024

Different immunomodulatory mechanisms are at work depending on the type of treatment and the genetic makeup of the cancer in RCC.

Taletrectinib Under NMPA Review in China for First-Line ROS1+ NSCLC

March 5th 2024

China’s National Medical Products Administration has accepted the second NDA for first-line taletrectinib for ROS1-positive non–small cell lung cancer.

NICE Recommends Dostarlimab Plus Chemo in MSI-High/dMMR Endometrial Cancer

March 5th 2024

The National Institute for Health and Care Excellence recommends the approval of dostarlimab plus chemotherapy for advanced/recurrent endometrial cancer.

2024 Outlook on Cancer Care: Striving to Overcome the Challenges

March 5th 2024

Although novel therapies have improved cancer care, cancer diagnoses have increased, with more than 2 million new cases estimated for 2024.

Porter Discusses FDA’s Call for Secondary Malignancies Boxed Warning on CAR T-Cell Therapies

March 5th 2024

David L. Porter, MD, discusses the decision by the FDA to call for a boxed warning for secondary malignancies on all approved CAR T-cell agents.

Immunotherapy Success Signals Paradigm Shift Toward Nonoperative Management in Select GI Cancers

March 4th 2024

Michael J. Overman, MD, discusses the potential advantages of using nonoperative immunotherapy-based approaches in select gastrointestinal cancers.

Pedersen Shares 2023 Year-End GI Malignancy Treatment Updates

March 4th 2024

Katrina S. Pedersen, MD, MS, shares updates in the treatment of gastrointestinal cancers, including biliary tract cancer and neuroendocrine tumors.

Levy Delves Into the Evolution of ADCs in NSCLC

March 4th 2024

Benjamin Philip Levy, MD, discusses lingering questions regarding the use of antibody-drug conjugates in lung cancer.

New Compound Takes Aim at CLL

March 4th 2024

Patients with chronic lymphocytic leukemia and related blood cancers are often prescribed targeted drugs called BTK inhibitors.

FDA Lifts Clinical Hold on Trial Investigating LN-145 in NSCLC

March 4th 2024

The partial clinical hold placed on the phase 2 IOV-LUN-202 trial of LN-145 in non–small cell lung cancer has been lifted by the FDA.

FDA Approval Sought for Mirdametinib in NF1-PN

March 4th 2024

SpringWorks Therapeutics has initiated a new drug application for mirdametinib in neurofibromatosis type 1-associated plexiform neurofibromas.